Investor Presentaiton

Solid Q2 2022/23, in line with expectations. 3 Organic growth 8% Reported EBIT margin ROIC 28%* 19%** *before special items of 20 million DKK related to the Atos Medical integration **after tax and before special items Kjell | Denmark Coloplast

View entire presentation